---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-26-000022"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:59:57.607205+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

## Summary
- Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
- Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.
- TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.
- Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.
- Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility.

## SEC filing metadata
- accession: 0001823239-26-000022
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/0001823239-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/mrvi-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-26-000022
- JSON: https://secwatch.observer/filing/0001823239-26-000022.json
- Plain text: https://secwatch.observer/filing/0001823239-26-000022.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: revenue $65.8 million, net income $(6.4) million. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: $65.8 million
  - Net income: $(6.4) million
  - Guidance: raised
  - Result: reported results
  source text: Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: • Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/0001823239-26-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.